Nitya Nathwani

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 653 citations · Full text

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson, Susanna Jacobus, Edie Weller et al. · New England Journal of Medicine · 2022 · 428 citations · Full text

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach et al. · The Lancet Haematology · 2023 · 139 citations

Transplantation-eligible Patients, Hematological Malignancy, Transplantation +11

Differential Effects of Apolipoprotein A-I–Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice

Xiaojun Li, Kuang‐Yuh Chyu, José Rocha Faria‐Neto et al. · Circulation · 2004 · 130 citations · Full text

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

Erin Reid, Gita Suneja, Richard F. Ambinder et al. · Journal of the National Comprehensive Cancer Network · 2018 · 103 citations · Full text